Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|February 12, 2013
Functional consequences of Wnt-induced dishevelled 2 phosphorylation in canonical and noncanonical Wnt signalingJosé M González-Sancho, Yoshimi Endo Greer, Cristina L Abrahams, et al.
Oncogene|November 25, 2025
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibitionDavid J Wisniewski, Donna Voeller, Yonit A Addissie, et al.
Cell Death & Disease|April 25, 2025
Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancerKei Kudo, Yoshimi Endo Greer, Daniel R Crooks, et al.
Cancer Research Communications|November 17, 2022
Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial HomeostasisYoshimi Endo Greer, Lidia Hernandez, Emily M J Fennell, et al.
The Oncologist|June 6, 2023
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaSarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, et al.
Pharmacology Research & Perspectives|August 5, 2022
Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpPEmily M J Fennell, Lucas J Aponte-Collazo, Joshua D Wynn, et al.
Oncotarget|May 3, 2018
ONC201 kills breast cancer cells in vitro by targeting mitochondriaYoshimi Endo Greer, Natalie Porat-Shliom, Kunio Nagashima, et al.
Research Square|December 3, 2025
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor VenetoclaxSabrina C D Daglish, Owen G Canterbury, Paul R Graves, et al.
Cell Death & Disease|June 29, 2026
Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclaxSabrina C D Daglish, Owen G Canterbury, Paul R Graves, et al.
Pageof 2